There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Prophase Labs (PRPH – Research Report) and Regulus (RGLS – Research Report) with bullish sentiments. Prophase Labs (PRPH) H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Prophase Labs today and set a price target of $14.00. The company's shares closed last Monday at $9.91. According to TipRanks.
https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-prophase-labs-prph-regulus-rgls?utm_source=advfn.com&utm_medium=referral
Regulus Therapeutics (NASDAQ:RGLS)
Historical Stock Chart
From Aug 2022 to Sep 2022 Click Here for more Regulus Therapeutics Charts.
Regulus Therapeutics (NASDAQ:RGLS)
Historical Stock Chart
From Sep 2021 to Sep 2022 Click Here for more Regulus Therapeutics Charts.